Cite
HARVARD Citation
Danese, S. et al. (2022). Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Lancet gastroenterology and hepatology. pp. 118-127. [Online].